Kymera Therapeutics, Inc.
KYMR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001815442
In the last 90 days, Kymera Therapeutics, Inc. insiders filed 0 open-market purchases and 5 sales; 276 institutions reported holding it in 13F filings for Q2 2026, worth $11.1B in total; no superinvestor holds it.
13F holders, Q2 2025
Institutional positions in Kymera Therapeutics, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 210
- +37 vs. Q1 2025
- Shares held
- 78.8M
- +5.94M (+8.2%) vs. Q1 2025
- Total value
- $3.44B
- +$1.44B (+72.2%) vs. Q1 2025
- New holders
- 63
- 70 more added
- Sold out
- 26
- 52 more reduced
1 institution that held it in Q1 2025 haven't filed for Q2 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting KYMR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 276 | $11.1B |
| Q1 2026 | 256 | $8.01B |
| Q4 2025 | 255 | $6.99B |
| Q3 2025 | 210 | $4.58B |
| Q2 2025 | 210 | $3.44B |
| Q1 2025 | 174 | $2.00B |
| Q4 2024 | 181 | $2.89B |
| Q3 2024 | 176 | $3.27B |
| Q2 2024 | 157 | $2.01B |
| Q1 2024 | 164 | $2.70B |
| Q4 2023 | 137 | $1.54B |
| Q3 2023 | 122 | $797.2M |
| Q2 2023 | 129 | $1.34B |
| Q1 2023 | 127 | $1.68B |
| Q4 2022 | 121 | $1.40B |
| Q3 2022 | 128 | $1.15B |
| Q2 2022 | 101 | $973.6M |
| Q1 2022 | 126 | $1.93B |
| Q4 2021 | 128 | $2.76B |
| Q3 2021 | 115 | $2.04B |
| Q2 2021 | 110 | $1.29B |
| Q1 2021 | 97 | $887.2M |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Kymera Therapeutics, Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Siren, L.L.C. | 3,428,150 | $149.6M | 7.74% | +187,837+5.8% | Added |
| BlackRock, Inc. | 4,148,260 | $181.0M | 0.00% | −134,643−3.1% | Reduced |
| Atlas Venture Life Science Advisors, LLC | 4,896,462 | $213.7M | 32.26% | 00.0% | Unchanged |
| Wellington Management Group LLP | 5,372,061 | $234.4M | 0.04% | −624,812−10.4% | Reduced |
| FMR LLC | 5,431,994 | $237.1M | 0.01% | +1,022,760+23.2% | Added |
| BVF Inc | 5,502,710 | $240.1M | 8.58% | +340,909+6.6% | Added |
| Vanguard Group Inc | 5,619,848 | $245.3M | 0.00% | +388,456+7.4% | Added |
| Avoro Capital Advisors LLC | 6,555,555 | $286.1M | 5.01% | +95,555+1.5% | Added |
| Baker Bros. Advisors LP | 6,651,429 | $290.3M | 2.82% | +655,500+10.9% | Added |
| Price T Rowe Associates Inc | 6,859,202 | $299.3M | 0.03% | +156,752+2.3% | Added |
| Aquilo Capital Management, LLC | 0 | $0 | 0.00% | −138,521−100.0% | Sold out |
| Affinity Asset Advisors, LLC | 0 | $0 | 0.00% | −100,000−100.0% | Sold out |
| First Trust Advisors LP | 0 | $0 | 0.00% | −93,795−100.0% | Sold out |
| E Fund Management Co., Ltd. | 0 | $0 | 0.00% | −71,863−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −65,399−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −31,537−100.0% | Sold out |
| Cinctive Capital Management LP | 0 | $0 | 0.00% | −23,492−100.0% | Sold out |
| Corebridge Financial, Inc. | 0 | $0 | 0.00% | −23,002−100.0% | Sold out |
| Natixis Advisors, L.P. | 0 | $0 | 0.00% | −14,334−100.0% | Sold out |
| Walleye Capital LLC | 0 | $0 | 0.00% | −10,059−100.0% | Sold out |
| HighVista Strategies LLC | 0 | $0 | 0.00% | −8,733−100.0% | Sold out |
| Exchange Traded Concepts, LLC | 0 | $0 | 0.00% | −3,693−100.0% | Sold out |
| Caitong International Asset Management Co., Ltd | 0 | $0 | 0.00% | −2,467−100.0% | Sold out |
| Ronald Blue Trust, Inc. | 0 | $0 | 0.00% | −247−100.0% | Sold out |
| Coldstream Capital Management Inc | 0 | $0 | 0.00% | −178−100.0% | Sold out |
| Clear Street Markets LLC | 0 | $0 | 0.00% | −140−100.0% | Sold out |
| Versant Capital Management, Inc | 0 | $0 | 0.00% | −83−100.0% | Sold out |
| Meeder Asset Management Inc | 0 | $0 | 0.00% | −72−100.0% | Sold out |
| Amundi | 0 | $0 | 0.00% | −40−100.0% | Sold out |
| CoreCap Advisors, LLC | 0 | $0 | 0.00% | −28−100.0% | Sold out |
| Stephens Consulting, LLC | 0 | $0 | 0.00% | −15−100.0% | Sold out |
| Hexagon Capital Partners LLC | 0 | $0 | 0.00% | −13−100.0% | Sold out |
| Federation des caisses Desjardins du Quebec | 0 | $0 | 0.00% | −10−100.0% | Sold out |
| True Wealth Design, LLC | 0 | $0 | 0.00% | −6−100.0% | Sold out |
| Global Financial Private Client, LLC | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Hemington Wealth Management | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Lindbrook Capital, LLC | – | – | – | – | Not filed |